- Email: [email protected]
5175151 Antiviral compounds and antihypertensive compounds
New Patents
Vlll
5175105 PROCESS FOR THE PRODUCTION OF UROKINASE USING SACCHAROMYES CEREVISIAE Bernd Meyhack, Jutta Heim, Rolf Burgi, Magden, Switzerland assigned to Ciba-Geigy Corporation Novel human plasminogen activators of the urokinase type are produced by yeast cells transformed with a hybrid vector comprising a DNA sequence coding for said human plasminogen activator. Novel hybrid vectors, yeast hosts transformed with such hybrid vectors and processes for the production thereof are also provided.
mula 1.0: See Patent for Chemical Structure (1 .O) and their pha~aceuti~ally acceptable salts and solvates. Pha~aceutical compositions containing compounds represented by Formula 1.O are disclosed. Also disclosed are methods of treating hypertension or a viral infection using compounds represented by Formulas 1.0. Also disclosed is a compound of Structure B See Putent for Chemical Structure B useful as an intermediate in producing compounds of Formula 1.0, A process for preparing the compounds of Formula 1.0 is also disclosed. In the process a compound of Structure B See Patent for Chemical Stmcture B is reacted with an alkoxide R loM-i- in a solvent comprising the corresponding alcohol RIOH of the alkoxide. OptionaIly, an organic cosolvent may be used with the solvent.
5175165 5175108 PLASMIDS FROM CORYNEBACTERIUM GLUTAMICUM AND PLASMID VECTORS DERIVED THEREFROM Frank Bachmann, Hans J Kutzner, Han Sonnen, Georg Thierbach, Petra-Sabine Kautz, Alfred Puhler, Andreas Schaefer, Moerfelden Waldorf, Federal Republic Of Germany assigned to Degussa Aktiengesellschaft The present invention relates to new plasmids isolated from Corynebacterium glutamicum, plasmid pGA 1 and pGA2, which are compatible with one another. In addition, the present invention relates to recombinant plasmids and to plasmid vectors (shuttle vectors) containing the new plasmids. The plasmids and plasmid vectors of the present invention are suitable for use with genetic engineering to improve bacteria strains.
5175151 ANTIVIRAL COMPOUNDS ANTIHYPERTENSIVE COMPOUNDS
AND
Adrian Afonso, Jay Weinstein, Margaret Gentles assigned to Schering Corporation Compounds useful as antihypertensive agents, or antiviral agents against DNA containing viruses, such as herpes group viruses, are disclosed. The compounds are represented by For-
ANTIVIRAL COMBINATIONS AND COMPOUNDS THEREFOR Todd A Blumenkopf, Thoma Spector, Devron R Averett, Robert W Morrison, Eric Bigham, Virgil Styles assigned to Burroughs Wellcome Co The present invention relates to novel ribonucleotide reductase inhibitors and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemotherapeutic treatment of virus infections, espectially viruses of the herpes group.
5175209 POROUS WAFER FOR SEGMENTED SYNTHESIS OF BIOPOLYMERS Kenneth L Beattie, James Frost assigned to Baylor College of Medicine A wafer for synthesizing biopolymers which includes a solid phase support material, a reaction chamber which receives and retains the support material and at least one inert porous material which allows flow through the wafer. Also included is a segmented wafer synthesis device comprising at least one, and preferably numerous, wafers for the simultaneous synthesis of multiple defined-sequenced biopolymers. Further there are process steps for synthesizing a variety of biopolymers. Synthetic polynucleotides have played a key role in studies of genetic organization through their use as primers
Vlll
5175105 PROCESS FOR THE PRODUCTION OF UROKINASE USING SACCHAROMYES CEREVISIAE Bernd Meyhack, Jutta Heim, Rolf Burgi, Magden, Switzerland assigned to Ciba-Geigy Corporation Novel human plasminogen activators of the urokinase type are produced by yeast cells transformed with a hybrid vector comprising a DNA sequence coding for said human plasminogen activator. Novel hybrid vectors, yeast hosts transformed with such hybrid vectors and processes for the production thereof are also provided.
mula 1.0: See Patent for Chemical Structure (1 .O) and their pha~aceuti~ally acceptable salts and solvates. Pha~aceutical compositions containing compounds represented by Formula 1.O are disclosed. Also disclosed are methods of treating hypertension or a viral infection using compounds represented by Formulas 1.0. Also disclosed is a compound of Structure B See Putent for Chemical Structure B useful as an intermediate in producing compounds of Formula 1.0, A process for preparing the compounds of Formula 1.0 is also disclosed. In the process a compound of Structure B See Patent for Chemical Stmcture B is reacted with an alkoxide R loM-i- in a solvent comprising the corresponding alcohol RIOH of the alkoxide. OptionaIly, an organic cosolvent may be used with the solvent.
5175165 5175108 PLASMIDS FROM CORYNEBACTERIUM GLUTAMICUM AND PLASMID VECTORS DERIVED THEREFROM Frank Bachmann, Hans J Kutzner, Han Sonnen, Georg Thierbach, Petra-Sabine Kautz, Alfred Puhler, Andreas Schaefer, Moerfelden Waldorf, Federal Republic Of Germany assigned to Degussa Aktiengesellschaft The present invention relates to new plasmids isolated from Corynebacterium glutamicum, plasmid pGA 1 and pGA2, which are compatible with one another. In addition, the present invention relates to recombinant plasmids and to plasmid vectors (shuttle vectors) containing the new plasmids. The plasmids and plasmid vectors of the present invention are suitable for use with genetic engineering to improve bacteria strains.
5175151 ANTIVIRAL COMPOUNDS ANTIHYPERTENSIVE COMPOUNDS
AND
Adrian Afonso, Jay Weinstein, Margaret Gentles assigned to Schering Corporation Compounds useful as antihypertensive agents, or antiviral agents against DNA containing viruses, such as herpes group viruses, are disclosed. The compounds are represented by For-
ANTIVIRAL COMBINATIONS AND COMPOUNDS THEREFOR Todd A Blumenkopf, Thoma Spector, Devron R Averett, Robert W Morrison, Eric Bigham, Virgil Styles assigned to Burroughs Wellcome Co The present invention relates to novel ribonucleotide reductase inhibitors and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemotherapeutic treatment of virus infections, espectially viruses of the herpes group.
5175209 POROUS WAFER FOR SEGMENTED SYNTHESIS OF BIOPOLYMERS Kenneth L Beattie, James Frost assigned to Baylor College of Medicine A wafer for synthesizing biopolymers which includes a solid phase support material, a reaction chamber which receives and retains the support material and at least one inert porous material which allows flow through the wafer. Also included is a segmented wafer synthesis device comprising at least one, and preferably numerous, wafers for the simultaneous synthesis of multiple defined-sequenced biopolymers. Further there are process steps for synthesizing a variety of biopolymers. Synthetic polynucleotides have played a key role in studies of genetic organization through their use as primers